A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs CTP 499 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 16 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 09 Jul 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2015 according to the ClinicalTrials.gov record.
    • 25 Apr 2014 Primary endpoint 'Change in Urinary-albumin:creatinine-ratio at 24 weeks' has not been met, according to a Concert Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top